Cargando…
Manufacturing Bacteriophages (Part 2 of 2): Formulation, Analytics and Quality Control Considerations
Within this second piece of the two-part series of phage manufacturing considerations, we are examining the creation of a drug product from a drug substance in the form of formulation, through to fill-finish. Formulation of a drug product, in the case of bacteriophage products, is often considered o...
Autores principales: | Moraes de Souza, Carolina, Tanir, Tayfun, Orellana, Marvin, Escalante, Aster, Koeris, Michael Sandor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467454/ https://www.ncbi.nlm.nih.gov/pubmed/34577595 http://dx.doi.org/10.3390/ph14090895 |
Ejemplares similares
-
Manufacturing Bacteriophages (Part 1 of 2): Cell Line Development, Upstream, and Downstream Considerations
por: Tanir, Tayfun, et al.
Publicado: (2021) -
Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization
por: Flint, Rohan, et al.
Publicado: (2023) -
Formulations for Bacteriophage Therapy and the Potential Uses of Immobilization
por: Rosner, Daniel, et al.
Publicado: (2021) -
Bacteriophage-insensitive mutants for high quality Crescenza manufacture
por: Chirico, Donatella, et al.
Publicado: (2014) -
Considerations for using bacteriophages for plant disease control
por: Jones, Jeffrey B., et al.
Publicado: (2012)